2015年2月6日讯/生物谷BIOON/--近日，勃林格殷格翰和礼来收获利好消息，两家公司的糖尿病联合用药Glyxambi获FDA批准。
FDA批准的Glyxambi是Jardiance (empagliflozin)和Trajenta (linagliptin)的联合用药治疗方式，这是美国首次将钠-葡萄糖联合转运体-2 （SGLT2）抑制剂(Jardiance)和二肽基肽酶-4抑制剂（DPP-4）联合使用制成片剂，用法是早晨服用，每日一次。
钠-葡萄糖联合转运体-2（SGLT2）抑制剂通过阻断血糖在肾脏中的重吸收来降低尿液的糖含量，而DPP-4抑制剂的作用是增加激素含量，刺激胰岛素的生成、以及降低肝糖原的分解。
勃林格殷格翰美国分公司的负责人Paul Fonteyne表示，钠-葡萄糖联合转运体-2（SGLT2）和DPP-4分别是两个已证明的治疗2型糖尿病的靶标，而此次将二者同时使用，为控制血糖提供了更多样的途径。礼来糖尿病部门的负责人 Mike Mason表示，近一半2型糖尿病患者未能有效地将血糖控制在推荐范围内，这次Glyxambi获批也是对两家公司努力的肯定。
英文原文
Boehringer Ingelheim and Eli Lilly are celebrating after getting the green light in the USA for their diabetes combination Glyxambi.
The Food and Drug Administration has approved Glyxambi， which combines Jardiance (empagliflozin) with Trajenta (linagliptin). It is the first treatment in the USA to combine the dual mechanisms of action of a sodium glucose co-transporter-2 inhibitor (Jardiance) and a dipeptidyl peptidase-4 inhibitor in a once-daily tablet， to be taken in the morning.
SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney， while DPP-4 inhibitors increase hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose.
Paul Fonteyne， president of Boehringer’s US subsidiary， said that with the dual inhibition of DPP-4 and SGLT2， “two proven targets in the treatment of type 2 diabetes，” now provides an option “to simultaneously address multiple pathways to improve glycaemic control”. Mike Mason， head of Lilly Diabetes in the USA， added that half of people with type 2 diabetes do not achieve recommended blood sugar control， claiming that approval of this first-in-class medicine “is also a testament to our alliance’s commitment” to the disease.